Enasidenib maintenance after transplant for IDH2-mutated AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies enasidenib to help keep acute myeloid leukemia (AML) under control after an allogeneic stem cell transplant in people with an IDH2 mutation. It may help reduce the chance of the leukemia coming back by targeting the mutation that drives the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML with an IDH2 mutation diagnosed at the start of your illness
- You had an allogeneic stem cell transplant (from a donor), and you’re in “maintenance” after transplant
- Your day-30 bone marrow test shows remission (less than 5% blasts), or you may qualify if MRD is present/allowed by the study
- You can take pills and don’t have an uncontrolled active infection or other serious uncontrolled health problem
- Your blood counts are adequate (neutrophils, hemoglobin, and platelets), or you may qualify with special infection treatment circumstances
- You have certain heart/liver/kidney and infection-safety lab levels, and you test negative for HIV and active hepatitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
This trial tests whether adding ivosidenib to an oral chemotherapy pill (azacitidine) helps prevent relapse in adults over 55 who have a specific IDH1 gene mutation and whose acute myeloid leukemia is in remission after intensive chemo.
This trial tests a new drug called HMPL-306 in people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It is for patients whose leukemia cells have a specific change in the IDH1 or IDH2 gene.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.